UPB · Upstream Bio, Inc.

Upstream Bio's Q1 2026 results reflect accelerated investment in its lead asset verekitug, with R&D expenses rising 42% year-over-year to $36.6 million due to increased clinical trial and manufacturing costs for ongoing Phase 2 programs in severe asthma, CRSwNP, and COPD, plus higher personnel expenses including share-based compensation. G&A expenses grew 19% to $8.1 million from elevated professional fees and staffing. This drove a net loss expansion to $40.6 million from $27.3 million in Q1 2025. Balance sheet remains solid with $294.6 million in cash, cash equivalents, and short-term investments as of March 31, 2026, supporting operations through 2027 amid no revenue guidance but clear pipeline milestones. CEO Rand Sutherland emphasized positioning verekitug for best-in-class efficacy via quarterly at-home dosing, supported by Phase 2 VALIANT top-line data from February 2026 showing significant reductions in asthma exacerbations and lung function gains. Strategic shifts include capping VENTURE COPD enrollment after 400+ participants to prioritize high-dose quarterly Phase 3 planning, with data now slated for H2 2027. Regulatory alignment via mid-2026 FDA meetings underpins Q1 2027 Phase 3 starts in asthma and CRSwNP, while long-term extension VALOUR achieved >90% retention and upcoming ATS/EAACI presentations will detail VIBRANT biomarker data, reinforcing verekitug's TSLP receptor inhibition profile in Type 2 inflammation.